Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) is a pioneering clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing breakthrough treatments for fibrotic diseases. The company leverages the therapeutic potential of integrin biology and TGF-β modulation to create therapies that could prevent or even reverse fibrosis, thereby addressing significant unmet medical needs.
Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule dual selective inhibitor of αvß6 and αvß1 integrins. It is currently in development for treating idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA for both IPF and PSC, as well as Orphan Drug Designation from the European Medicines Agency.
The company is actively advancing several clinical programs:
- INTEGRIS-PSC Phase 2a Trial: Recent interim results demonstrated bexotegrast’s potential in treating PSC, showing reductions in Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels with statistical significance at the 160 mg dose.
- BEACON-IPF Phase 2b/3 Trial: This adaptive trial design aims to accelerate the development timeline by immediately transitioning from Phase 2b to Phase 3 upon enrollment completion.
- PLN-1474: A small molecule selective inhibitor for treating nonalcoholic steatohepatitis (NASH) with liver fibrosis.
- PLN-101095: In Phase 1, this dual-selective inhibitor targets integrins αvß8 and αvß1 for treating solid tumors.
- PLN-101325: A monoclonal antibody agonist targeting muscular dystrophies.
Founded by world-renowned researchers from UCSF, Pliant Therapeutics combines expertise in fibrosis biology and small molecule chemistry to develop novel therapies. The company also aims to build a patient registry to enhance the understanding of fibrotic disease progression and to support biomarker discovery.
With a strong pipeline, significant regulatory designations, and ongoing successful clinical trials, Pliant Therapeutics is well-positioned to make substantial advancements in treating fibrotic diseases. For more information and the latest updates, visit their website or follow them on social media platforms like X, LinkedIn, Facebook, and YouTube.
Pliant Therapeutics (Nasdaq: PLRX) has resumed its PLN-74809 Phase 2a PET imaging trial, with preliminary results expected in the first half of 2021. The company reported strong progress in their Phase 2a trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), anticipated to complete enrollment by late 2021 and early 2022, respectively. Financially, R&D expenses rose to $17.9 million, leading to a net loss of $19.0 million, while cash reserves stood at $276.9 million, sufficient for operations into 2023.
Pliant Therapeutics (Nasdaq: PLRX) announced the successful completion of the Phase 1 trial for PLN-1474, a selective integrin αvβ1 inhibitor aimed at treating nonalcoholic steatohepatitis (NASH) with liver fibrosis. The trial, involving 84 healthy volunteers, demonstrated the drug's rapid absorption and tolerability without significant adverse effects. Following the trial, PLN-1474 is now under the stewardship of Novartis, per their 2019 Collaboration and License Agreement, which includes significant milestone payments and royalties for Pliant.
Pliant Therapeutics, a clinical stage biotechnology company focused on fibrosis treatment, has announced participation in key virtual investor events. Management will take part in the Cowen 41st Annual Health Care Conference from March 1-4, 2021, with a panel discussion led by President and CEO Bernard Coulie on March 1 at 10:30 a.m. ET. Additionally, they will engage with investors on March 17 during Citi's 2021 Winter West Coast Biotech Virtual Bus Tour. Pliant's lead drug candidate is PLN-74809, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
Pliant Therapeutics (Nasdaq: PLRX) announced the appointment of Dr. David Pyott to its Board of Directors, strengthening its leadership as the company advances its clinical stage portfolio. Dr. Pyott, former Chairman and CEO of Allergan, brings over 30 years of pharmaceutical experience, transforming Allergan into a global leader. He aims to support Pliant in developing innovative treatments for fibrosis. Pliant's lead candidate, PLN-74809, targets idiopathic pulmonary fibrosis and primary sclerosing cholangitis, with ongoing Phase 2a trials.
Pliant Therapeutics (Nasdaq: PLRX) has appointed Gregory P. Cosgrove, M.D., as Vice President of Clinical Development. Dr. Cosgrove will spearhead the strategic execution of the Idiopathic Pulmonary Fibrosis (IPF) clinical development program for PLN-74809, a dual selective inhibitor currently in Phase 2a trials. His extensive experience in pulmonary fibrosis research is expected to enhance Pliant's clinical efforts. PLN-74809 has received Orphan Drug Designation from the FDA for both IPF and primary sclerosing cholangitis.
Pliant Therapeutics (Nasdaq: PLRX) announced its participation in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The company will feature a fireside chat with CEO Bernard Coulie on November 23, 2020, at 10:00 AM ET, available on their website. Pliant focuses on developing therapies for fibrosis, with lead candidate PLN-74809 in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The session will be archived for 90 days post-event.
Pliant Therapeutics (Nasdaq: PLRX) reported its Q3 2020 results, highlighting significant progress in clinical programs despite COVID-19 challenges. The company successfully executed its IPO and advanced multiple indications in its pipeline, notably PLN-74809 for idiopathic pulmonary fibrosis and COVID-19 related ARDS. Financially, the company experienced related party revenue of $4.8 million, with R&D expenses rising to $16.9 million, leading to a net loss of $16.5 million. Pliant maintains a strong cash position of $294 million, sufficient to fund operations into 2023.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) will present a poster at The Liver Meeting® 2020, hosted by AASLD, from November 13-16, 2020. The poster, titled "Profiling Fibrosis Regression in a Rat Model of Non-Alcoholic Steatohepatitis" (Abstract #0321), will be available online for registered participants. Pliant, focused on fibrosis treatment, has two main candidates: PLN-74809, in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and PLN-1474, in Phase 1 trials for liver fibrosis associated with NASH.
Pliant Therapeutics (Nasdaq: PLRX) has appointed Mike Ouimette as the new general counsel and corporate secretary. Bringing over 20 years of legal expertise, Ouimette previously held executive positions at Portola Pharmaceuticals and Onyx Pharmaceuticals. His appointment aims to enhance Pliant's legal and regulatory strategies as the company progresses its lead drug candidate, PLN-74809, through Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Pliant focuses on developing innovative therapies for treating fibrosis.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced its data presentation on PLN-74809 during the ATS 2020 Virtual Sessions on Sept. 24, 2020. PLN-74809 is an oral dual selective integrin inhibitor being evaluated for treating fibrotic diseases like idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The treatment has received Orphan Drug Designation by the FDA for both indications and is currently in Phase 2a trials for IPF and PSC. The presentation will be accessible to registered attendees until Nov. 10, 2020.
FAQ
What is the current stock price of Pliant Therapeutics (PLRX)?
What is the market cap of Pliant Therapeutics (PLRX)?
What does Pliant Therapeutics, Inc. specialize in?
What is bexotegrast (PLN-74809)?
What are the ongoing clinical trials for bexotegrast?
What regulatory designations has bexotegrast received?
Who are the founders of Pliant Therapeutics?
What other products are in Pliant’s pipeline?
How is Pliant Therapeutics advancing fibrotic disease research?
Where can I find more information about Pliant Therapeutics?
What recent achievements has Pliant Therapeutics announced?
How does Pliant Therapeutics contribute to patient care?
